Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of ...

Key Points Interested in Rigel Pharmaceuticals, Inc.? Here are five stocks we like better. Strong Q2 performance: Rigel ...

Schorno said 2026 guidance was increased and tightened to “approximately $285 million to $295 million,” with “approximately $255 million to $265 million in net product sales, excluding VEPPANU and ...

(RIGL) on Tuesday reported earnings of $17.3 million in its second quarter. On a per-share basis, the South San Francisco, California-based company said it had profit of 88 cents. The drug developer ...

Rigel reported net income of $17.3 million, or $0.93 basic and $0.88 diluted per share, compared to $59.6 million, or $3.33 basic and $3.28 diluted per share, for the same period of 2025. As noted ...

Haribo is synonymous with gummy candies, and markets more than 100 different shapes. One of them dates back to the company's ...

Allen Semino, a determined resident of Barangay Mansacul in Sigma town, knows these struggles all too well but recently ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter 2026, ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel ...

Nvidia is creating a kind of continuous feedback loop, where its current generation Vera CPUs speed up the development of ...

A new contract for the Royal Saudi Navy’s MMSC program reveals additional design work and delays, pushing final construction ...